Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Rheumatology | 8 | 2023 | 615 | 3.080 |
Why?
|
Vasculitis | 6 | 2023 | 521 | 3.030 |
Why?
|
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 11 | 2023 | 225 | 2.880 |
Why?
|
Internal Medicine | 10 | 2022 | 1051 | 2.660 |
Why?
|
Teaching | 11 | 2020 | 1170 | 2.350 |
Why?
|
Fellowships and Scholarships | 11 | 2022 | 1117 | 2.250 |
Why?
|
Internship and Residency | 16 | 2022 | 5880 | 1.780 |
Why?
|
Referral and Consultation | 11 | 2020 | 3600 | 1.700 |
Why?
|
Microscopic Polyangiitis | 4 | 2015 | 46 | 1.470 |
Why?
|
Glucocorticoids | 9 | 2023 | 2161 | 1.440 |
Why?
|
Clinical Clerkship | 3 | 2022 | 564 | 1.420 |
Why?
|
Education, Medical, Graduate | 11 | 2022 | 2373 | 1.360 |
Why?
|
Rheumatic Diseases | 3 | 2023 | 649 | 1.350 |
Why?
|
Curriculum | 10 | 2022 | 3743 | 1.050 |
Why?
|
Prednisone | 5 | 2021 | 1563 | 1.020 |
Why?
|
Clinical Competence | 9 | 2020 | 4792 | 1.010 |
Why?
|
Students, Medical | 4 | 2024 | 1936 | 0.970 |
Why?
|
Immunosuppressive Agents | 8 | 2023 | 4174 | 0.950 |
Why?
|
Hospitalists | 2 | 2018 | 294 | 0.910 |
Why?
|
Fever | 2 | 2022 | 1618 | 0.880 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 4 | 2015 | 694 | 0.860 |
Why?
|
Confusion | 2 | 2022 | 278 | 0.850 |
Why?
|
Systemic Vasculitis | 1 | 2023 | 36 | 0.850 |
Why?
|
Antibodies, Antineutrophil Cytoplasmic | 5 | 2023 | 289 | 0.840 |
Why?
|
Remission Induction | 9 | 2023 | 2396 | 0.830 |
Why?
|
Autoimmune Diseases | 5 | 2023 | 2244 | 0.750 |
Why?
|
Faculty, Medical | 4 | 2020 | 1203 | 0.730 |
Why?
|
Problem-Based Learning | 3 | 2020 | 356 | 0.730 |
Why?
|
Muscle Weakness | 1 | 2023 | 412 | 0.690 |
Why?
|
Purpura | 2 | 2017 | 117 | 0.680 |
Why?
|
Medicine | 2 | 2018 | 942 | 0.680 |
Why?
|
Education, Medical | 2 | 2023 | 1725 | 0.610 |
Why?
|
Paraneoplastic Syndromes | 1 | 2019 | 155 | 0.590 |
Why?
|
Azathioprine | 7 | 2023 | 354 | 0.570 |
Why?
|
Peroxidase | 3 | 2016 | 609 | 0.560 |
Why?
|
Inpatients | 6 | 2020 | 2548 | 0.550 |
Why?
|
Chondrosarcoma | 1 | 2019 | 296 | 0.550 |
Why?
|
Edema | 2 | 2017 | 766 | 0.540 |
Why?
|
Skull Base | 1 | 2019 | 292 | 0.530 |
Why?
|
Arthritis, Infectious | 1 | 2020 | 347 | 0.530 |
Why?
|
Dermatomyositis | 1 | 2019 | 258 | 0.520 |
Why?
|
Skull Base Neoplasms | 1 | 2019 | 270 | 0.510 |
Why?
|
Education, Medical, Undergraduate | 2 | 2021 | 1070 | 0.500 |
Why?
|
Learning | 5 | 2022 | 1740 | 0.500 |
Why?
|
Lymphomatoid Granulomatosis | 1 | 2015 | 16 | 0.490 |
Why?
|
Headache | 2 | 2022 | 1256 | 0.490 |
Why?
|
Cyclophosphamide | 7 | 2020 | 2218 | 0.490 |
Why?
|
Educational Measurement | 4 | 2020 | 1254 | 0.480 |
Why?
|
Interdisciplinary Communication | 2 | 2019 | 931 | 0.460 |
Why?
|
Hypereosinophilic Syndrome | 1 | 2015 | 97 | 0.460 |
Why?
|
Antirheumatic Agents | 4 | 2017 | 1372 | 0.440 |
Why?
|
Antiphospholipid Syndrome | 1 | 2015 | 165 | 0.420 |
Why?
|
Calciphylaxis | 1 | 2015 | 130 | 0.420 |
Why?
|
Health Services Needs and Demand | 1 | 2020 | 1403 | 0.400 |
Why?
|
Medical History Taking | 1 | 2014 | 774 | 0.360 |
Why?
|
Arterial Occlusive Diseases | 1 | 2015 | 748 | 0.360 |
Why?
|
Lumbar Vertebrae | 1 | 2020 | 1879 | 0.350 |
Why?
|
Humans | 66 | 2024 | 761504 | 0.350 |
Why?
|
Drug Therapy, Combination | 7 | 2023 | 6310 | 0.340 |
Why?
|
Career Choice | 1 | 2016 | 756 | 0.330 |
Why?
|
Interprofessional Relations | 1 | 2015 | 990 | 0.320 |
Why?
|
Physical Examination | 1 | 2014 | 1255 | 0.310 |
Why?
|
Secondary Prevention | 1 | 2014 | 1475 | 0.300 |
Why?
|
Biomedical Research | 1 | 2023 | 3429 | 0.290 |
Why?
|
Myeloblastin | 3 | 2016 | 101 | 0.290 |
Why?
|
Skin | 2 | 2019 | 4484 | 0.280 |
Why?
|
Autoantibodies | 4 | 2022 | 2116 | 0.270 |
Why?
|
Decision Support Techniques | 1 | 2016 | 1998 | 0.260 |
Why?
|
Severity of Illness Index | 4 | 2016 | 15842 | 0.260 |
Why?
|
Polymyalgia Rheumatica | 2 | 2018 | 52 | 0.260 |
Why?
|
Communication | 2 | 2017 | 3873 | 0.260 |
Why?
|
Schools, Medical | 2 | 2022 | 879 | 0.250 |
Why?
|
Manikins | 2 | 2019 | 243 | 0.250 |
Why?
|
Needs Assessment | 3 | 2020 | 1139 | 0.240 |
Why?
|
Self-Assessment | 2 | 2017 | 396 | 0.230 |
Why?
|
Attitude of Health Personnel | 4 | 2019 | 3889 | 0.220 |
Why?
|
Exanthema | 2 | 2017 | 503 | 0.200 |
Why?
|
Critical Care | 1 | 2015 | 2696 | 0.200 |
Why?
|
Diagnosis, Differential | 5 | 2020 | 12974 | 0.200 |
Why?
|
Recurrence | 5 | 2022 | 8465 | 0.200 |
Why?
|
Takayasu Arteritis | 2 | 2014 | 105 | 0.190 |
Why?
|
Pemphigoid, Benign Mucous Membrane | 1 | 2022 | 113 | 0.190 |
Why?
|
Polychondritis, Relapsing | 1 | 2021 | 29 | 0.190 |
Why?
|
Heart Diseases | 1 | 2014 | 2781 | 0.180 |
Why?
|
Pemphigoid, Bullous | 1 | 2022 | 112 | 0.180 |
Why?
|
Pharynx | 1 | 2023 | 432 | 0.180 |
Why?
|
Meningitis | 1 | 2021 | 217 | 0.170 |
Why?
|
Sjogren's Syndrome | 1 | 2021 | 237 | 0.170 |
Why?
|
Giant Cell Arteritis | 2 | 2014 | 306 | 0.160 |
Why?
|
Double-Blind Method | 5 | 2015 | 12341 | 0.150 |
Why?
|
Steroids | 1 | 2023 | 929 | 0.150 |
Why?
|
Mycophenolic Acid | 1 | 2020 | 348 | 0.150 |
Why?
|
Drug Administration Schedule | 2 | 2018 | 4853 | 0.150 |
Why?
|
Thinking | 1 | 2020 | 320 | 0.140 |
Why?
|
Encephalitis | 1 | 2021 | 438 | 0.140 |
Why?
|
Ribonucleoproteins | 1 | 2019 | 372 | 0.140 |
Why?
|
Attitude | 1 | 2021 | 775 | 0.140 |
Why?
|
Crohn Disease | 2 | 2021 | 2279 | 0.140 |
Why?
|
Biopsy | 2 | 2019 | 6766 | 0.130 |
Why?
|
Infectious Disease Medicine | 1 | 2016 | 49 | 0.130 |
Why?
|
Patient Care Management | 1 | 2019 | 302 | 0.130 |
Why?
|
Otorhinolaryngologic Diseases | 1 | 2016 | 97 | 0.130 |
Why?
|
Arthritis, Psoriatic | 1 | 2018 | 219 | 0.130 |
Why?
|
Educational Status | 1 | 2023 | 2522 | 0.130 |
Why?
|
Malignant Atrophic Papulosis | 1 | 2015 | 7 | 0.120 |
Why?
|
Arthritis, Rheumatoid | 2 | 2022 | 3763 | 0.120 |
Why?
|
Aneurysm | 1 | 2018 | 337 | 0.120 |
Why?
|
Fibromuscular Dysplasia | 1 | 2015 | 55 | 0.120 |
Why?
|
Treatment Outcome | 11 | 2022 | 64680 | 0.120 |
Why?
|
Male | 18 | 2022 | 360804 | 0.120 |
Why?
|
Fatal Outcome | 1 | 2019 | 1834 | 0.120 |
Why?
|
Pulmonary Medicine | 1 | 2016 | 221 | 0.110 |
Why?
|
Feedback | 1 | 2017 | 791 | 0.110 |
Why?
|
Workload | 1 | 2020 | 844 | 0.110 |
Why?
|
Hospitals, Teaching | 1 | 2018 | 1156 | 0.110 |
Why?
|
Autoimmune Diseases of the Nervous System | 1 | 2014 | 75 | 0.110 |
Why?
|
Academic Medical Centers | 3 | 2019 | 2759 | 0.110 |
Why?
|
Methotrexate | 1 | 2020 | 1719 | 0.110 |
Why?
|
Pilot Projects | 2 | 2018 | 8631 | 0.110 |
Why?
|
Arthroscopy | 1 | 2020 | 969 | 0.110 |
Why?
|
Pediatrics | 2 | 2019 | 3589 | 0.100 |
Why?
|
Nephrology | 1 | 2016 | 263 | 0.100 |
Why?
|
Professional Role | 1 | 2015 | 314 | 0.100 |
Why?
|
Interpersonal Relations | 1 | 2020 | 1436 | 0.100 |
Why?
|
Immunoglobulin G | 2 | 2015 | 4544 | 0.100 |
Why?
|
Pain | 2 | 2017 | 5073 | 0.100 |
Why?
|
Female | 18 | 2023 | 392644 | 0.100 |
Why?
|
United States | 6 | 2022 | 72334 | 0.100 |
Why?
|
Anti-Inflammatory Agents | 1 | 2021 | 1809 | 0.100 |
Why?
|
Neurology | 2 | 2016 | 780 | 0.090 |
Why?
|
Adult | 12 | 2023 | 221177 | 0.090 |
Why?
|
Burnout, Professional | 1 | 2020 | 704 | 0.090 |
Why?
|
Eye Diseases | 1 | 2016 | 653 | 0.090 |
Why?
|
Lung Diseases, Interstitial | 1 | 2019 | 918 | 0.090 |
Why?
|
Immunomodulation | 1 | 2014 | 549 | 0.090 |
Why?
|
Consensus | 2 | 2019 | 3123 | 0.090 |
Why?
|
Physicians | 3 | 2019 | 4591 | 0.090 |
Why?
|
Observer Variation | 1 | 2016 | 2606 | 0.090 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2014 | 664 | 0.090 |
Why?
|
Massachusetts | 3 | 2018 | 8830 | 0.090 |
Why?
|
Ophthalmology | 1 | 2016 | 550 | 0.080 |
Why?
|
Focus Groups | 1 | 2015 | 1413 | 0.080 |
Why?
|
Pulmonary Artery | 1 | 2018 | 1927 | 0.080 |
Why?
|
Hospitals | 1 | 2022 | 3882 | 0.080 |
Why?
|
Hospitalization | 2 | 2020 | 10723 | 0.080 |
Why?
|
Sensitivity and Specificity | 1 | 2023 | 14666 | 0.080 |
Why?
|
Middle Aged | 13 | 2021 | 220895 | 0.070 |
Why?
|
Body Composition | 1 | 2017 | 2426 | 0.070 |
Why?
|
Administration, Oral | 1 | 2015 | 4021 | 0.070 |
Why?
|
Cross-Over Studies | 1 | 2013 | 2078 | 0.070 |
Why?
|
Adrenal Cortex Hormones | 1 | 2015 | 1880 | 0.070 |
Why?
|
Lung Diseases | 1 | 2016 | 1909 | 0.070 |
Why?
|
Vascular Diseases | 1 | 2015 | 1161 | 0.070 |
Why?
|
Dermatology | 1 | 2016 | 918 | 0.070 |
Why?
|
Nervous System Diseases | 1 | 2016 | 1666 | 0.070 |
Why?
|
Terminology as Topic | 1 | 2013 | 1530 | 0.070 |
Why?
|
Kidney Diseases | 1 | 2016 | 2091 | 0.060 |
Why?
|
Immunologic Factors | 1 | 2014 | 1589 | 0.060 |
Why?
|
Venous Thromboembolism | 1 | 2018 | 1866 | 0.060 |
Why?
|
Time Factors | 2 | 2018 | 39967 | 0.060 |
Why?
|
Qualitative Research | 1 | 2015 | 3023 | 0.060 |
Why?
|
Quality of Life | 2 | 2023 | 13367 | 0.060 |
Why?
|
Psychiatry | 1 | 2016 | 1693 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 3 | 2020 | 36426 | 0.060 |
Why?
|
Hospital Mortality | 1 | 2017 | 5294 | 0.050 |
Why?
|
Disease Progression | 2 | 2017 | 13506 | 0.050 |
Why?
|
Telemedicine | 1 | 2020 | 3051 | 0.050 |
Why?
|
Aged, 80 and over | 4 | 2020 | 58976 | 0.050 |
Why?
|
Databases, Factual | 1 | 2017 | 7967 | 0.050 |
Why?
|
B-Lymphocytes | 1 | 2015 | 4758 | 0.050 |
Why?
|
Antigens, CD20 | 1 | 2022 | 200 | 0.050 |
Why?
|
Anti-Bacterial Agents | 1 | 2020 | 7407 | 0.050 |
Why?
|
Myocardium | 1 | 2014 | 4726 | 0.050 |
Why?
|
Aged | 8 | 2019 | 169289 | 0.040 |
Why?
|
Mucous Membrane | 1 | 2022 | 659 | 0.040 |
Why?
|
Program Evaluation | 2 | 2019 | 2495 | 0.040 |
Why?
|
Reproducibility of Results | 1 | 2016 | 20098 | 0.040 |
Why?
|
Endarterectomy | 1 | 2018 | 196 | 0.040 |
Why?
|
Cicatrix | 1 | 2022 | 798 | 0.030 |
Why?
|
Education | 1 | 2018 | 537 | 0.030 |
Why?
|
Young Adult | 2 | 2019 | 59243 | 0.030 |
Why?
|
Prospective Studies | 2 | 2018 | 54425 | 0.030 |
Why?
|
Trust | 1 | 2019 | 530 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2022 | 10209 | 0.030 |
Why?
|
Canada | 1 | 2019 | 2122 | 0.030 |
Why?
|
Neoplasms | 1 | 2021 | 22170 | 0.030 |
Why?
|
Patient Admission | 1 | 2019 | 1367 | 0.020 |
Why?
|
Echocardiography, Transesophageal | 1 | 2018 | 1086 | 0.020 |
Why?
|
Syndrome | 1 | 2018 | 3267 | 0.020 |
Why?
|
Receptors, Interleukin-6 | 1 | 2012 | 226 | 0.020 |
Why?
|
Fatigue | 1 | 2018 | 1552 | 0.020 |
Why?
|
Cell Count | 1 | 2015 | 1835 | 0.020 |
Why?
|
Retrospective Studies | 4 | 2022 | 80636 | 0.020 |
Why?
|
Dyspnea | 1 | 2018 | 1347 | 0.020 |
Why?
|
Program Development | 1 | 2014 | 1297 | 0.020 |
Why?
|
Cohort Studies | 2 | 2020 | 41487 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2019 | 3461 | 0.020 |
Why?
|
Boston | 1 | 2019 | 9326 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2019 | 3745 | 0.020 |
Why?
|
Immunotherapy | 1 | 2021 | 4652 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39106 | 0.020 |
Why?
|
Leadership | 1 | 2014 | 1385 | 0.010 |
Why?
|
Lung | 1 | 2020 | 10000 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7390 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2012 | 10766 | 0.010 |
Why?
|
Melanoma | 1 | 2018 | 5709 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2019 | 7879 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 2018 | 5821 | 0.010 |
Why?
|
Prognosis | 1 | 2015 | 29625 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2018 | 20570 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2018 | 13380 | 0.010 |
Why?
|
Concepts
(211)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(75)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_